Your browser doesn't support javascript.
loading
Combinatorial development of nebulized mRNA delivery formulations for the lungs.
Jiang, Allen Y; Witten, Jacob; Raji, Idris O; Eweje, Feyisayo; MacIsaac, Corina; Meng, Sabrina; Oladimeji, Favour A; Hu, Yizong; Manan, Rajith S; Langer, Robert; Anderson, Daniel G.
Afiliação
  • Jiang AY; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Witten J; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Raji IO; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Eweje F; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • MacIsaac C; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Meng S; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Oladimeji FA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Hu Y; Department of Anesthesiology, Boston Children's Hospital, Boston, MA, USA.
  • Manan RS; Harvard and MIT Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Langer R; Harvard/MIT MD-PhD Program, Boston, MA, USA.
  • Anderson DG; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Nat Nanotechnol ; 19(3): 364-375, 2024 Mar.
Article em En | MEDLINE | ID: mdl-37985700
ABSTRACT
Inhaled delivery of mRNA has the potential to treat a wide variety of diseases. However, nebulized mRNA lipid nanoparticles (LNPs) face several unique challenges including stability during nebulization and penetration through both cellular and extracellular barriers. Here we develop a combinatorial approach addressing these barriers. First, we observe that LNP formulations can be stabilized to resist nebulization-induced aggregation by altering the nebulization buffer to increase the LNP charge during nebulization, and by the addition of a branched polymeric excipient. Next, we synthesize a combinatorial library of ionizable, degradable lipids using reductive amination, and evaluate their delivery potential using fully differentiated air-liquid interface cultured primary lung epithelial cells. The final combination of ionizable lipid, charge-stabilized formulation and stability-enhancing excipient yields a significant improvement in lung mRNA delivery over current state-of-the-art LNPs and polymeric nanoparticles.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Excipientes / Nanopartículas Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Excipientes / Nanopartículas Idioma: En Ano de publicação: 2024 Tipo de documento: Article